u/yara_bakken

Agreed, and it is why FGP printing the column and gradient on the certificate is genuinely useful rather than decorative.

That service reports area percent by default. Worth stating, since the thread has been comparing it to a mass figure.

What did the confidence interval look like?

Agreed. Appetite is the leading indicator and the scale is the lagging one. Watch the first, not the second.

stopping is a plan, not an event

write down where you are before you change anything

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Date of analysis anchors the result to a manufacturing period.

teodor_jansen is right that the band matters more than the peak. Consistency across lots is the finding.

discontinuation rate is a result, not a footnote

cost and supply are the two most common reasons and both are legitimate

the log is cumulative, that is the whole value of it

Chased a ghost peak for three weeks. It was the plumbing. It is always the plumbing.

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

you cannot report to two decimals off that baseline

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

vendor, compound, batch, service, result — that is the template

Did you run a blank between injections?

report the method or do not report the number

Is that baseline drawn by the software or by hand?

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

Wrote down where I was before changing anything. That single page made the following six months interpretable.

Right. And a blank between injections settles the carryover argument before it starts.

What was the claim on the certificate you are comparing against?

That reading assumes area percent and net peptide content are the same number. They are not, and the report says which it is.

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

I would not treat appetite returning as a sign of doing it wrong. It is the expected sequence.

Appetite is the proximal effect and weight is the lagging integrated outcome, which is why watching appetite gives you an earlier and more honest signal.

Push back: an open-label extension tells you about the people who stayed. That is a different question.

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

date of analysis matters as much as the number

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

What wavelength, and what was the gradient?

Bought a second-hand instrument and learned more in six months of fixing it than in three years of reading traces.

LC-MS for identity, UV for relative quantity

What did system suitability look like on that sequence?

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

you cannot report to two decimals off that baseline

area percent unless the report says otherwise